According to a national study conducted by Emerson College Polling, President Trump has started his term with a 49% approval rating. He also got a 41% disapproval rate, while 10% are neutral.

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals. The drug, Journavx, or suzetrigine, was approved to treat moderate to severe ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

FDA Approves First New Non-Opioid Pain Pill in Decades By India Edwards HealthDay Reporter FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally ...

Jan. 31, 2025 – The FDA has approved a new non-opioid oral drug for acute pain in adults. It is the first new class of non-opioid pain medicine approved in over 20 years, providing effective ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally ...

The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery. Pain is registered in ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally ...